Agios Pharmaceuticals, Inc. (AGIO) stock
Close on Nov 12, 2026Market cap $1.90BP/E –Yield –
Agios Pharmaceuticals, Inc. grew revenue 214.4% to $140.84M over the twelve months to Sep 30, 2026. Free cash flow was -$335.97M. At the latest close the market valued the company at $1.90B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.90B
- P/E ratio
- –
- Price to sales
- 13.46
- Price to book
- 1.94
- Dividend yield
- –
- Free cash flow yield
- -17.72%
Fundamentals
- Revenue
- $140.84M
- Net income
- -$372.90M
- EPS, diluted
- -$6.32
- Free cash flow
- -$335.97M
- Book value per share
- $16.40
- Diluted shares
- 60M
Trading
- Next earnings
- Feb 11, 2027 (estimated, before the open)
- Previous close
- $32.82
- Open
- $32.56
- Day's range
- $31.55 – $32.76
- Volume
- 497,039
- Average volume (20 days)
- 1,271,473
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000
- Beta (5 years)
- 1.41
- 52-week range
- $22.24 – $46.00
- RSI (14 days)
- 46.8
- Volatility (1 year)
- 79.8%
- Relative volume
- 0.44×
- WACC
- 11.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AGIO | S&P 500 | Difference | AGIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.0% | -2.7% | +5.7 pts | ||
| 3 months | -7.2% | -1.7% | −5.4 pts | ||
| Year to date | +16.7% | +11.9% | +4.8 pts | ||
| 1 year | -27.2% | +12.0% | −39.2 pts | ||
| 3 years | +50.2% | +78.2% | −27.9 pts | +14.5% | +21.2% |
| 5 years | -24.4% | +73.2% | −97.6 pts | -5.4% | +11.6% |
| 10 years | -50.5% | +309.6% | −360.2 pts | -6.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Agios Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Update
About Agios Pharmaceuticals
Pharmaceutical Preparations
Agios is a commercial-stage biopharmaceutical company focused on discovering and developing therapies for rare hematologic conditions and genetic metabolic disorders. The company's lead commercial product is mitapivat, an oral small-molecule pyruvate kinase activator marketed under the brand names Pyrukynd and Aqvesme for indications including pyruvate kinase deficiency and alpha- or beta-thalassemia. In addition to commercializing mitapivat, Agios advances a clinical development pipeline featuring investigational candidates such as tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company serves adult and pediatric patient populations diagnosed with rare hematological and metabolic diseases.
Company profile, executives and historyAgios Pharmaceuticals stock: common questions
What is Agios Pharmaceuticals's stock price?
AGIO closed at $31.76 on Nov 12, 2026, down 3.23% on the day. Over the past 52 weeks it traded between $22.24 and $46.00.
What is Agios Pharmaceuticals's market cap?
Agios Pharmaceuticals was worth $1.90B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AGIO's P/E ratio?
Agios Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$6.32), so it has no meaningful P/E ratio.
How much revenue does Agios Pharmaceuticals make?
Agios Pharmaceuticals reported revenue of $140.84M for the twelve months to Sep 30, 2026, up 214.4% from a year earlier.
Does Agios Pharmaceuticals pay a dividend?
No. Agios Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Agios Pharmaceuticals report earnings next?
Agios Pharmaceuticals is expected to report Q4 FY2026 results on Feb 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AGIO stock performed over the past year?
Including dividends, AGIO returned -27.2% over the past year, against +12.0% for the S&P 500.
How many AGIO shares are sold short?
7M shares were sold short at the latest FINRA report, 11.05% of the float, or 5.2 days of average trading volume.
Who are Agios Pharmaceuticals's competitors?
Companies most similar to Agios Pharmaceuticals by business, industry and size include AKBA, ZVRA, ETON, CYTK, RIGL.
See a number that looks wrong?